MindMed Adds Chief Development Officer with FDA Phase 2 Psilocybin Clinical Trial Experience
MindMed Adds Chief Development Officer with FDA Phase 2 Psilocybin Clinical Trial Experience News provided by Share this article Psychedelic Pharmaceutical Scientist and Clinical Pharmacologist Robert Barrow Appointed as Chief Development Officer NEW YORK, Jan. 14, 2021 /PRNewswire/ -- MindMed (NEO: MMED), (OTCQB: MMEDF), (DE: MMQ), a leading psychedelic medicine biotech company today announced the addition of Robert Barrow, an accomplished pharmaceutical executive, as Chief Development Officer. Mr. Barrow has over a decade of experience leading drug development programs aimed at identifying...
Source: prnewswire.com